Sarepta Awarded $115.2M in Vyondys 53 Patent Case: Report

Seeking AlphaDec 21 07:00

Mizuho Securities Maintains Sarepta Therapeutics(SRPT.US) With Buy Rating, Maintains Target Price $200

Futu NewsDec 21 02:31 · Ratings

Mizuho Securities Reaffirms Their Buy Rating on Sarepta Therapeutics (SRPT)

TipRanksDec 21 01:50 · Ratings

Sell Rating on Sarepta Therapeutics Due to Limited LGMD Market Potential and Overestimated Elevidys Projections

TipRanksDec 21 01:26 · Ratings

4 Biotech Stocks Most Wall Street Analysts Are Bullish About

Zacks Dec 20 01:30

25 U.S. 'Highest Conviction' Stocks – UBS

Seeking AlphaDec 19 23:48